Charles River Laboratories International (NYSE:CRL – Get Free Report) and Champions Oncology (NASDAQ:CSBR – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.
Valuation and Earnings
This table compares Charles River Laboratories International and Champions Oncology”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Charles River Laboratories International | $4.02 billion | 3.37 | -$144.34 million | ($4.85) | -58.42 |
| Champions Oncology | $59.42 million | 1.13 | -$1.17 million | ($0.08) | -60.19 |
Profitability
This table compares Charles River Laboratories International and Champions Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Charles River Laboratories International | -5.96% | 15.75% | 6.51% |
| Champions Oncology | -1.87% | -27.48% | -3.84% |
Volatility & Risk
Charles River Laboratories International has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Charles River Laboratories International and Champions Oncology, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Charles River Laboratories International | 1 | 3 | 12 | 0 | 2.69 |
| Champions Oncology | 1 | 0 | 0 | 0 | 1.00 |
Charles River Laboratories International presently has a consensus target price of $255.65, suggesting a potential downside of 9.77%. Given Charles River Laboratories International’s stronger consensus rating and higher possible upside, equities analysts clearly believe Charles River Laboratories International is more favorable than Champions Oncology.
Insider & Institutional Ownership
98.9% of Charles River Laboratories International shares are held by institutional investors. Comparatively, 41.3% of Champions Oncology shares are held by institutional investors. 1.3% of Charles River Laboratories International shares are held by insiders. Comparatively, 46.4% of Champions Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Charles River Laboratories International beats Champions Oncology on 10 of the 14 factors compared between the two stocks.
About Charles River Laboratories International
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
About Champions Oncology
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
